Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Off-Label Unleashed? Amarin Win Suggests Firms Still Need Strong Data To Skirt FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Court blesses combination of statements and disclosures that must accompany Vascepa promotions in a ruling that rejects FDA's narrow interpretation of 2012 Caronia case.


Related Content

Amarin's Omega-3 Fair Trade Complaint Reaches Regulatory Dead End
Trade Panel Bolsters FDA's View In Amarin Omega-3 Complaint
FDA Plants Oversight Flag On Amarin Trade Claim Against Omega-3 Ingredients
FDA Objects To Amarin Trade Complaint Against Omega-3 Ingredients
Amarin Seeks ITC Action Against Products 'Cloaked' As Dietary Supplements
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization
FDA Makes It Formal, Rescinds SPA For Amarin’s ANCHOR Study
Off-Label Enforcement, Not Promotion, May See First Changes After Free Speech Ruling


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts